A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
Trial details
- Registry ID
- NCT06830629
- Drugs studied
- MZE829
TrialRedline tracks 1 clinical trial sponsored by Maze Therapeutics: 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 2 Study of MZE829 in Adults With APOL1 Kidney DiseaseNCT06830629 | MZE829 | Recruiting | 2026-09Estimated |
Names as written in the registry records.
NCT06830629 · Maze Therapeutics
Before: 56 participants (planned). After: 74 participants (planned).